FLT3 and acute myeloid leukemia: Our study focused on the prognostic impact of FLT3–ITD mutations and their ratio in a series of 2901 adult patients enrolled in the consecutive multicenter AML trials of the PETHEMA group in the pre-FLT3 inhibitors era, 579 of whom harbor FLT3–ITD mutations.